Matteo Parolin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Matteo Parolin has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
F. Dassie
Department of Medicine (DIMED), University of Padua, Padova, Italy
3 shared publications- Pietro Maffei
Department of Medicine, Padua University, Padua, Italy
3 shared publications R. Vettor
Department of Medicine (DIMED), University of Padua, Padova, Italy
3 shared publicationsFrancesca Dassie
Department of Medicine, Internal Medicine-3, University of Padova, Padova, Italy
2 shared publications- Roberto Mioni
Dipartimento di Medicina – Clinica Medica 3, Az. Ospedaliera di Padova, Università di Padova, Padova, Italia
2 shared publications - Roberto Vettor
Center for Metabolic Diseases and Nutrition, IRCCS Humanitas Research Hospital, Rozzano, Italy
2 shared publications
Latest Publications
- Open Access
- 14 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (S 01) , E126-E127
Ectopic mediastinal parathyroid diagnosed by contrast-enhanced endoscopic ultrasound-guided fine-needle aspiration and eluate parathormone level
Primary hyperparathyroidism is defined as an elevated serum calcium with an elevated or inappropriately normal parathyroid hormone (PTH), and rarely it can be due to an ectopic mediastinal parathyroid [1]. We describe a 68-year-old woman with a new diagnosis of primary hyperparathyroidism due to a suspected mediastinal parathyroid. Laboratory tests revealed an elevated serum calcium (11.5 mg/dL [normal range 8.8–10.1]), decreased serum phosphorus (2.1 mg/dL [2.5–4.5]), high parathormone (150 pg/mL [12–72]), and hypercalciuria (313 mg/day [>250 mg/day]). The patient also had multiple co-morbidities, including atrial fibrillation, obesity, and a multinodular goiter. According to recent guidelines, parathyroidectomy was indicated [1]. We performed endoscopic ultrasound (EUS) to identify the precise location of the ectopic parathyroid, using a linear echoendoscope (GF-UCT180; Olympus Medical, Tokyo, Japan) connected to an Arietta S70 (Hitachi-Aloka, Japan) [2] [3]. We detected an ill-defined hypoechoic inhomogeneous lesion (19 × 8 mm) at 20 cm from the upper incisors on the right side of the esophagus ([Video 1]). As we deemed B-mode scanning insufficient to proceed with EUS-guided fine-needle aspiration (EUS-FNA) safely, we investigated the lesion further with contrast-enhanced EUS after injection of one vial of Sonovue (Bracco, Italy), which showed a hyperenhanced lesion [4]. EUS-FNA was then performed with a 22G needle (Expect; Boston Scientific, USA). The aspirate was diluted in 2 mL normal saline and a real-time rapid PTH assay was performed. The cytologic appearance and PTH level on the diluted eluate (>2500 pg/mL) were diagnostic of an ectopic parathyroid ([Fig. 1]). For the detection of ectopic adenomas, current guidelines [1] recommend imaging methods such as neck ultrasound, scintigraphy, positron-emission tomography, and computed tomography, which may be inconclusive in some cases. EUS-FNA and PTH testing on the eluate, which is usually more sensitive than the cytology of the specimen, should be considered. We believe that EUS-FNA is safe in these often co-morbid and frail patients, allowing appropriate referral for a major surgical intervention such as parathyroidectomy [5]. Endoscopy_UCTN_Code_CCL_1AF_2AC Article published online: 06 February 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 14 January 2025
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 57 (S 01) , E126-E127
Open AccessEctopic mediastinal parathyroid diagnosed by contrast-enhanced endoscopic ultrasound-guided fine-needle aspiration and eluate parathormone level
Primary hyperparathyroidism is defined as an elevated serum calcium with an elevated or inappropriately normal parathyroid hormone (PTH), and rarely it can be due to an ectopic mediastinal parathyroid [1]. We describe a 68-year-old woman with a new diagnosis of primary hyperparathyroidism due to a suspected mediastinal parathyroid. Laboratory tests revealed an elevated serum calcium (11.5 mg/dL [normal range 8.8–10.1]), decreased serum phosphorus (2.1 mg/dL [2.5–4.5]), high parathormone (150 pg/mL [12–72]), and hypercalciuria (313 mg/day [>250 mg/day]). The patient also had multiple co-morbidities, including atrial fibrillation, obesity, and a multinodular goiter. According to recent guidelines, parathyroidectomy was indicated [1]. We performed endoscopic ultrasound (EUS) to identify the precise location of the ectopic parathyroid, using a linear echoendoscope (GF-UCT180; Olympus Medical, Tokyo, Japan) connected to an Arietta S70 (Hitachi-Aloka, Japan) [2] [3]. We detected an ill-defined hypoechoic inhomogeneous lesion (19 × 8 mm) at 20 cm from the upper incisors on the right side of the esophagus ([Video 1]). As we deemed B-mode scanning insufficient to proceed with EUS-guided fine-needle aspiration (EUS-FNA) safely, we investigated the lesion further with contrast-enhanced EUS after injection of one vial of Sonovue (Bracco, Italy), which showed a hyperenhanced lesion [4]. EUS-FNA was then performed with a 22G needle (Expect; Boston Scientific, USA). The aspirate was diluted in 2 mL normal saline and a real-time rapid PTH assay was performed. The cytologic appearance and PTH level on the diluted eluate (>2500 pg/mL) were diagnostic of an ectopic parathyroid ([Fig. 1]). For the detection of ectopic adenomas, current guidelines [1] recommend imaging methods such as neck ultrasound, scintigraphy, positron-emission tomography, and computed tomography, which may be inconclusive in some cases. EUS-FNA and PTH testing on the eluate, which is usually more sensitive than the cytology of the specimen, should be considered. We believe that EUS-FNA is safe in these often co-morbid and frail patients, allowing appropriate referral for a major surgical intervention such as parathyroidectomy [5]. Endoscopy_UCTN_Code_CCL_1AF_2AC Article published online: 06 February 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
- 15 December 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (24) , 9554
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Polycystic ovary syndrome (PCOS) is characterized by elevated androgen production and subclinical changes in cardiovascular and metabolic risk markers. Total cholesterol, high-density lipoprotein (HDL) cholesterol, fasting glucose, and fasting insulin appear to increase specifically in PCOS compared with fertile women. PCOS also confers an increased risk of cardiometabolic disease in later life. Novel biomarkers such as serum’s cholesterol efflux capacity and blood-derived macrophage activation profile may assist in more accurately defining the cardiometabolic risk profile in these women. Aldosterone antagonists, androgen receptor antagonists, 5α-reductase inhibitors, and synthetic progestogens are used to reduce hyperandrogenism. Because increased insulin secretion enhances ovarian androgen production, short-term treatment with metformin and other hypoglycemic agents results in significant weight loss, favorable metabolic changes, and testosterone reduction. The naturally occurring inositols display insulin-sensitizing effects and may be also used in this context because of their safety profile. Combined oral contraceptives represent the drug of choice for correction of androgen-related symptoms. Overall, PCOS management remains focused on specific targets including assessment and treatment of cardiometabolic risk, according to disease phenotypes. While new options are adding to established therapeutic approaches, a sometimes difficult balance between efficacy and safety of available medications has to be found in individual women.
- 15 December 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (24) , 9554
Open AccessPharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Polycystic ovary syndrome (PCOS) is characterized by elevated androgen production and subclinical changes in cardiovascular and metabolic risk markers. Total cholesterol, high-density lipoprotein (HDL) cholesterol, fasting glucose, and fasting insulin appear to increase specifically in PCOS compared with fertile women. PCOS also confers an increased risk of cardiometabolic disease in later life. Novel biomarkers such as serum’s cholesterol efflux capacity and blood-derived macrophage activation profile may assist in more accurately defining the cardiometabolic risk profile in these women. Aldosterone antagonists, androgen receptor antagonists, 5α-reductase inhibitors, and synthetic progestogens are used to reduce hyperandrogenism. Because increased insulin secretion enhances ovarian androgen production, short-term treatment with metformin and other hypoglycemic agents results in significant weight loss, favorable metabolic changes, and testosterone reduction. The naturally occurring inositols display insulin-sensitizing effects and may be also used in this context because of their safety profile. Combined oral contraceptives represent the drug of choice for correction of androgen-related symptoms. Overall, PCOS management remains focused on specific targets including assessment and treatment of cardiometabolic risk, according to disease phenotypes. While new options are adding to established therapeutic approaches, a sometimes difficult balance between efficacy and safety of available medications has to be found in individual women.
- 6 July 2020
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 44 (2) , 209-221
Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?
Background Acromegaly is disease associated with a specific cardiomyopathy. Hitherto, it has been widely understood that acromegaly carries an increased risk of arrhythmia. Purpose In this review we show that evidences are limited to a small number of case–control studies that reported increased rates of premature ventricular beats (PVB) but no more significant arrhythmia. In contrast, there are several studies that have reported impaired preclinical markers of arrhythmia, including reduced heart rate variability, increased late potentials, QT interval dispersion, impaired heart rate recovery after physical exercise and left ventricular dysynchrony. Whilst these markers are associated with an adverse cardiovascular prognosis in the general population, they do not have a high independent positive predictive accuracy for arrhythmia. In acromegaly, case reports have described sudden cardiac death, ventricular tachyarrhythmia and advanced atrio-ventricular block that required implantation of a cardio-defibrillator or permanent pacemaker. Treatment with somatostatin analogues can reduce cardiac dysrhythmia in some cases by reducing heart rate, PVBs and QT interval. Pegvisomant reduces mean heart rate. Pasireotide is associated with QT prolongation. In the absence of good quality data on risk of arrhythmia in acromegaly, the majority of position statements and guidelines suggest routine 12-lead electrocardiography (ECG) and transthoracic echocardiography (TTE) in every patient at diagnosis and then follow up dependent on initial findings.
- 6 July 2020
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 44 (2) , 209-221
Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?
Background Acromegaly is disease associated with a specific cardiomyopathy. Hitherto, it has been widely understood that acromegaly carries an increased risk of arrhythmia. Purpose In this review we show that evidences are limited to a small number of case–control studies that reported increased rates of premature ventricular beats (PVB) but no more significant arrhythmia. In contrast, there are several studies that have reported impaired preclinical markers of arrhythmia, including reduced heart rate variability, increased late potentials, QT interval dispersion, impaired heart rate recovery after physical exercise and left ventricular dysynchrony. Whilst these markers are associated with an adverse cardiovascular prognosis in the general population, they do not have a high independent positive predictive accuracy for arrhythmia. In acromegaly, case reports have described sudden cardiac death, ventricular tachyarrhythmia and advanced atrio-ventricular block that required implantation of a cardio-defibrillator or permanent pacemaker. Treatment with somatostatin analogues can reduce cardiac dysrhythmia in some cases by reducing heart rate, PVBs and QT interval. Pegvisomant reduces mean heart rate. Pasireotide is associated with QT prolongation. In the absence of good quality data on risk of arrhythmia in acromegaly, the majority of position statements and guidelines suggest routine 12-lead electrocardiography (ECG) and transthoracic echocardiography (TTE) in every patient at diagnosis and then follow up dependent on initial findings.
- Open Access
- 1 January 2020
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 16 (1) , 69-71
Dome-and-dart T Waves and Hyperthyroidism – A Case Report
We briefly describe a case of a 31-year-old man with persistent hyperthyroidism, despite medical treatment with high dose methimazole. Twelve-lead 24-hour Holter monitoring showed bifid (or dome-and-dart) T waves and echocardiography revealed mild left ventricle dilatation. Hyperthyroidism was eventually treated with total thyroidectomy, and thereafter, T waves became normal and the left ventricle returned to normal dimensions. Hyperthyroidism should be considered among the differential diagnoses when T wave abnormalities are observed on electrocardiogram and when mild left ventricle dilatation is observed on an echocardiogram. The correction of hyperthyroidism can reverse these abnormalities.
- 1 January 2020
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 16 (1) , 69-71
Open AccessDome-and-dart T Waves and Hyperthyroidism – A Case Report
We briefly describe a case of a 31-year-old man with persistent hyperthyroidism, despite medical treatment with high dose methimazole. Twelve-lead 24-hour Holter monitoring showed bifid (or dome-and-dart) T waves and echocardiography revealed mild left ventricle dilatation. Hyperthyroidism was eventually treated with total thyroidectomy, and thereafter, T waves became normal and the left ventricle returned to normal dimensions. Hyperthyroidism should be considered among the differential diagnoses when T wave abnormalities are observed on electrocardiogram and when mild left ventricle dilatation is observed on an echocardiogram. The correction of hyperthyroidism can reverse these abnormalities.
- 9 September 2019
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 43 (3) , 279-287
Acromegaly and ultrasound: how, when and why?
Acromegaly is a rare disease caused by an excess of growth hormone and insulin-like growth factor 1. It is usually diagnosed because of typical signs such as macroglossia, acral enlargement, jaw prognathism and malocclusion. Systemic complications are a major cause of morbidity and mortality in acromegaly, and many patients remain undiagnosed for several years. Increased ultrasound (US) application in the general population, and including among acromegaly patients, has revealed many suggestive features which, taken together with clinical suspicion, could induce suspicion of this disease.
- 9 September 2019
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 43 (3) , 279-287
Acromegaly and ultrasound: how, when and why?
Acromegaly is a rare disease caused by an excess of growth hormone and insulin-like growth factor 1. It is usually diagnosed because of typical signs such as macroglossia, acral enlargement, jaw prognathism and malocclusion. Systemic complications are a major cause of morbidity and mortality in acromegaly, and many patients remain undiagnosed for several years. Increased ultrasound (US) application in the general population, and including among acromegaly patients, has revealed many suggestive features which, taken together with clinical suspicion, could induce suspicion of this disease.
- 2 May 2019
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (18) , E31
Cutis Verticis Gyrata Associated with Acromegaly
A 37-year-old man presented with excessive sweating, headaches, and increasing skin folds on his scalp. MRI showed a pituitary adenoma, and a diagnosis of acromegaly was made.
- 2 May 2019
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (18) , E31
Cutis Verticis Gyrata Associated with Acromegaly
A 37-year-old man presented with excessive sweating, headaches, and increasing skin folds on his scalp. MRI showed a pituitary adenoma, and a diagnosis of acromegaly was made.
- 17 September 2018
- Published by Springer Nature in Pituitary
- Vol. 21 (6) , 653-662
Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis
Multiple studies investigated preclinical markers of peripheral vascular damage in acromegaly (ACRO) reporting discordant results. The aim of this study was to run a meta-analysis to examine whether intima media thickness (IMT), flow mediated dilation (FMD) and arterial pulse wave velocity (PWV) are affected in acromegalic patients and to assess the impact of effective treatment of growth hormone excess on these outcomes.
- 17 September 2018
- Published by Springer Nature in Pituitary
- Vol. 21 (6) , 653-662
Preclinical markers of atherosclerosis in acromegaly: a systematic review and meta-analysis
Multiple studies investigated preclinical markers of peripheral vascular damage in acromegaly (ACRO) reporting discordant results. The aim of this study was to run a meta-analysis to examine whether intima media thickness (IMT), flow mediated dilation (FMD) and arterial pulse wave velocity (PWV) are affected in acromegalic patients and to assess the impact of effective treatment of growth hormone excess on these outcomes.
- 21 September 2017
- Published by Springer Nature in Pituitary
- Vol. 21 (1) , 16-24
Guidelines versus real life practice: the case of colonoscopy in acromegaly
The aim of this study is to investigate guideline application and colonoscopy findings in real-life practice in acromegaly.
- 21 September 2017
- Published by Springer Nature in Pituitary
- Vol. 21 (1) , 16-24
Guidelines versus real life practice: the case of colonoscopy in acromegaly
The aim of this study is to investigate guideline application and colonoscopy findings in real-life practice in acromegaly.